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| INTRODUCTION
Papillary thyroid cancer (PTC) is the most common histologic type of thyroid cancer which accounts for 85%-90% of thyroid malignancies, and its incidence has been increasing over the years.
1 PTCs rarely behave as aggressive tumours clinically, with a 10-year survival rate of approximately 95%. 2 However, a small proportion of cases with aggressive features at presentation develop early distant metastasis or relapse and are associated with adverse outcomes.
In recent decades, there has been significant progress in understanding the molecular profiles and the pathogenesis of thyroid cancer, especially papillary thyroid carcinoma (PTC). Several molecular markers have been shown to have promising prognostic value in PTC patients including BRAF mutation and TERT promoter mutations. [3] [4] [5] [6] However, there are still continuing debates regarding which molecular markers should be used or how to combine them to better assess patients' prognosis. [7] [8] [9] In this meta-analysis, we aimed to investigate the clinicopathological implication of concurrent BRAF and TERT promoter mutations on PTC patients.
| MATERIALS AND METHODS

| Literature search
We searched for relevant articles in four electronic databases, including PubMed, Web of Science, Scopus and VHL from inception to September 2016. The following search term was used: BRAF AND
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Egger's regression test and funnel plot were carried out to further assess the presence of publication bias and calculated by Meta-Essentials:
Workbook for meta-analysis. 13 A P value <.05 was considered statistically significant publication bias.
| RESULTS
After searching four electronic databases and deleting duplicates, we found 111 articles for abstract screening step. Following title and abstract screening, 22 potential studies were selected for full-text reading. We further excluded 11 studies that did not meet the inclusion criteria after this step. Finally, 11 studies with 3911 PTC patients were included for final analysis (Figure 1 ).
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| Study characteristics
The characteristics of included studies are described in Table 1 . 
| Clinicopathological aggressiveness of PTCs with BRAF+/TERT+ vs PTCs with BRAF+ only or TERT+ only
Our results showed that PTCs harbouring BRAF+/TERT+ were significantly associated with more aggressive clinical courses as compared to tumours with BRAF+ only (Table 2 ). In addition, PTCs with BRAF+/ TERT+ also showed its increased aggressiveness in several clinical features (pT3/T4, extrathyroidal extension, advanced AJCC stage and tumour recurrence) when compared to PTCs harbouring TERT promoter mutation only (Table 2 ).
When we compared PTCs to either BRAF or TERT promoter mutation alone, there were no significant differences in the clinicopathological features between these two groups, except PTCs with TERT mutation only are more likely to metastasize to distant organs than PTCs harbouring only BRAF mutation ( (Table 3 ).
We also found that PTCs with BRAF+ only were associated with increased risk for aggressive tumour behaviours when compared to PTCs with BRAF−/TERT− such as higher risk for pT3/T4, extrathyroidal extension, nodal metastasis and advanced AJCC stage (Table 3) .
| Between-study heterogeneity assessment
We used sensitivity analysis by removing each of the included studies to find which studies influenced the degree of heterogeneity. All significant pooled results following the leave-one-out method remained unaffected. We could not perform meta-regression to further explore the origin of heterogeneity because of small numbers of included studies.
| Risk of bias assessment and quality of studies
The NOS tool was used to assess the quality of included studies. All of included studies were retrospective studies, and the number of stars awarded to each study ranged from five to six stars. Details of given stars within each domain of NOS are described in Table 4 .
| Publication bias
Funnel plot observation did not show strong evidence of publication bias among the set of studies. In addition, Egger's regression test of all effects did not suggest any evidence of publication bias (data not shown).
| DISCUSSION
Efforts to investigate the prognostic implication of clinicopathological features in PTCs have shown several clinical factors have been shown to have prognostic value such as old age, large tumour size, the presence of nodal and distant metastasis or extrathyroidal extension.
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The understanding of pathogenesis and molecular profiles in thyroid cancer has been much improved in recent years with the rapid growth of translational medicine. Therefore, investigating the usefulness of genetic events as trustworthy prognostic markers for risk stratification and patient management is essential.
Since 2003, the significant role of BRAF mutations, especially BRAF V600E, in tumour aggressiveness has been extensively studied.
In several published meta-analyses, the BRAF V600E has been summarized to correlate with aggressive clinical course in PTC patients, such as increased rate of extrathyroidal extension and nodal metastasis. 22, 23 TERT promoter mutation, the more recently discovered mutation in thyroid cancer, has been found to associate with aggressive clinicopathological features and poor outcomes in PTCs, especially its association with increased risk for distant metastasis. 7, 8, 24 Xing and colleagues first demonstrated that coexisting BRAF V600E and TERT FU, follow-up; MF, multifocality; ETE, extrathyroidal extension; LNM, lymph node metastasis; DM, distant metastasis; TR, tumour recurrence; ND, no description. Y indicates that the study was evaluated for the corresponding clinicopathological factor; N indicates that the study was not evaluated for the corresponding clinicopathological factor.
promoter mutations define a group of PTCs with even worse clinicopathological outcomes. 7 However, conflicting results were reported in other studies. 14, 15, 17 The TERT promoter mutations were found to be most likely in coexistence with BRAF V600E while the number of cases harbouring TERT promoter mutations alone is very rare. 9, 17, 18 It is still unclear why TERT promoter mutations most likely occur in cooperation with BRAF mutation in the same PTC. This association was also reported in melanomas 25 and thus suggests that such a relationship between these two oncogenic genetic events may be a general phenomenon in human cancer. Because of the small number of PTCs with only TERT promoter mutations, it is very difficult to observe any statistical difference between the molecular groups in individual studies.
Therefore, there is a definite need to perform a meta-analysis to overcome the limitation of small sample sizes of individual studies.
Our meta-analysis provided strong evidence that PTCs with coexisting BRAF and TERT promoter mutations were associated with a significantly increased risk for tumour aggressiveness and recurrence when compared to PTCs with BRAF or TERT promoter mutation alone. promoter mutation only can help predict a significant risk for distant metastasis, a fatal event, in PTCs. Additionally, the authors did not as- siveness. The combination of these mutations helps stratify PTC patients into distinct risk groups and better assess patients' outcome.
